https://montrealgazette.com/news/world/pfizer-is-testing-a-pill-that-if-successful-could-become-first-ever-home-cure-for-covid-19 Skip to Content SIGN UP Introducing 5 FP Newsletters: Energy, Economy, Investor, Work and Finance Financial Post: Introducing 5 Newsletters Sign Up Now> Manage Print Subscription Sections Search Search montrealgazette.com [ ] Perform search Montreal Gazette Share Close Share this Story: Pfizer is testing a pill that, if successful, could become first-ever home cure for COVID-19 * Copy Link * Email Email * Facebook Facebook * Twitter Twitter * Reddit Reddit * Pinterest Pinterest * LinkedIn LinkedIn * Tumblr Tumblr Subscribe Main Menu Search montrealgazette.com [ ] Perform search * News + Local News o Off-Island Gazette o West Island Gazette o COVID-19 + Quebec + National o COVID-19 + PostPandemic + World + Videos + Podcasts + Weather + Archives * Opinion + Columnists + Editorials + Aislin and other editorial cartoons * Sports + Hockey Inside Out + Hockey o Hockey Inside Out o Montreal Canadiens o NHL o World Juniors o Laval Rocket + Football o Montreal Alouettes o CFL o NFL + Soccer o MLS o Club de Foot Montreal + Baseball + Basketball o NBA o NCAA + Tennis + Golf o Golf Videos + Auto Racing * Business + FP Markets + FP Headlines + FP Money + Energy + Local Business o Open during COVID o Aerospace o Personal Finance o Real Estate o Retail + Technology o Gaming o Internet o Personal Tech o Science o Tech-Biz + Small Business + Montreal's Top Employers * Arts + Local Arts + Montreal movies o Movie Listings + Television o TV Listings + Montreal theatre + Music + Books + Celebrity * Life + Shopping Essentials + Fashion & Beauty + Food o Recipes o Local Food Reviews + Health o Healthing o Diet & Fitness o Family & Child o Men o Women o Seniors o Sexual Health + Diet & Fitness + Parenting + Relationships + Homes o Buying and Selling o Condos o Decorating o Renovating o Gardening o Vacation Homes + Travel + Royals + Puzzles + New York Times Crossword + Comics + Advice + Horoscopes + Contests * Obituaries + Browse Notices + Place an Obituary + Place an In Memoriam * Classifieds + Place an Ad + Celebrations + Real Estate + Local Directory + This Week's Flyers + Jobs + Auction * Driving * Healthing * The GrowthOp * ePaper * Subscribe + Our Offers + My Account + FAQ * News * Opinion * Sports * Business * Arts * Life * Driving * Healthing * The GrowthOp * ePaper * Share via email * Share on Facebook * Share on Twitter * Open more share options Close Share this Story: Pfizer is testing a pill that, if successful, could become first-ever home cure for COVID-19 + Copy Link + Email Email + Facebook Facebook + Twitter Twitter + Reddit Reddit + Pinterest Pinterest + LinkedIn LinkedIn + Tumblr Tumblr Breadcrumb Trail Links 1. World 2. News Pfizer is testing a pill that, if successful, could become first-ever home cure for COVID-19 Classed as a 'protease inhibitor', it has been formulated to attack the "spine" of the SARS-CoV-2 virus and stop it replicating in our nose, throats and lungs Author of the article: The Telegraph The Telegraph Paul Nuki Publishing date: Apr 26, 2021 * 9 hours ago * 4 minute read * Join the conversation Pfizer is creating a pill that if successful could be the first home-cure for COVID-19 Pfizer is creating a pill that if successful could be the first home-cure for COVID-19 Photo by Getty Images Article content At two anonymous Pfizer buildings, one in the U.S. and one in Belgium, a remarkable experiment is under way. Up to 60 volunteers, all clean-living adults aged between 18 and 60, are being given the first pill specifically designed to stop Covid-19. If the trial is successful, it is just possible a home cure for Covid-19 will become available later this year. U.K. Prime Minister Boris Johnson, who announced the formation of an "Antivirals Taskforce" last week specifically to invest in such products, will no doubt be scanning his text messages for early updates. We apologize, but this video has failed to load. Try refreshing your browser, or tap here to see other videos from our team. Pfizer is testing a pill that, if successful, could become first-ever home cure for COVID-19 Back to video Close sticky video The molecule being tested is a bespoke antiviral code-named PF-07321332. Classed as a "protease inhibitor", it has been formulated to attack the "spine" of the SARS-CoV-2 virus and stop it replicating in our nose, throats and lungs. It was protease inhibitors that turned the tide on the spread of HIV in the UK and around the world. Now researchers hope they may be on the brink of a similar pandemic-busting breakthrough. Advertisement Story continues below This advertisement has not loaded yet, but your article continues below. Article content "If they have moved to this stage they will be quietly optimistic," said Penny Ward, a visiting professor in pharmaceutical medicine at King's College London and a pioneer in the development of Tamiflu, an antiviral that combats seasonal and pandemic flu. "The question will be about how the drug is tolerated... They will be going like the clappers". The antiviral pill was developed from scratch during the current pandemic, Dafydd Owen, director of medicinal chemistry at Pfizer, told a private symposium of the Division of Medicinal Chemistry last month. The first seven milligrams of the compound - no more than a raindrop -- were made in late July 2020. By late October, they'd made 100 grams. Just two weeks later, they had more than a kilogram in the bag. It took 210 researchers to do it, said Owen. Advertisement Story continues below This advertisement has not loaded yet, but your article continues below. Article content If they have moved to this stage they will be quietly optimistic Pfizer is keeping schtum about the detail of the lab tests it has completed but says it has demonstrated "potent in vitro antiviral activity against SARS-CoV-2", as well as activity against other coronaviruses, raising the prospect of a cure for the common cold as well as future pandemic threats. "We have designed PF-07321332 as a potential oral therapy that could be prescribed at the first sign of infection, without requiring that patients are hospitalised or in critical care", said Mikael Dolsten, chief scientific officer and president of worldwide research, development and medical at Pfizer, in a statement released last month. According to Ward, Pfizer's scientists will have most likely established the drug's "potent" action against SARS-CoV-2 by deploying it against infected human tissue cultures, including lung tissue, in a laboratory. "Once you know it works in vitro, it's all about establishing its tolerance in animals and then humans," she said. Advertisement Story continues below This advertisement has not loaded yet, but your article continues below. Article content The Sunday Telegraph has obtained copies of the documents given to participants who are now entering the first human trials. "To date, the study drug has not been administered to humans," say the documents which were formally approved on February 8 this year. "The safety of the study drug has been studied in animals. In these animal studies, no significant risks or safety events of concern were identified, and the study drug did not cause side effects at any of the dose levels that will be used in clinical studies." Those who have signed up for the trial are in for an intensive few months. The trial is split into three phases and will run for 145 days, with another 28 days added for "screening and dosing". For all participants, there will be several overnight stays. Advertisement Story continues below This advertisement has not loaded yet, but your article continues below. Article content More On This Topic 1. Canada's Prime Minister Justin Trudeau watches as his wife Sophie Gregoire is inoculated with AstraZeneca's vaccine against coronavirus disease in Ottawa. Federal vaccine advisory committee recommends AstraZeneca vaccine for 30 year olds and older 2. Returning traveller Alain Wiesenthal has a COVID-19 test at Pearson Airport in Toronto on January 26, 2021. Wiesenthal was returning from an essential trip to Israel via New York. Israel finds heart inflammation in people who received Pfizer COVID-19 shot "You are here today as a possible participant in a drug research study sponsored by Pfizer Incorporated," say the briefing documents. "Taking part in this study is voluntary... If you are not completely honest about your health history, you may be harmed by being in this study." The "randomised, double-blind, placebo-controlled, single- and multiple-dose escalation study" is designed to see how well or otherwise different dosing regimens are tolerated in humans while the active compound is maintained in the body. PF-07321332 will be administered in combination with low doses of ritonavir, an antiviral used to treat HIV. It acts as a "booster" to increase the amount of PF-07321332 in participants' blood. Advertisement Story continues below This advertisement has not loaded yet, but your article continues below. Article content Phase 1 of the trial is designed to see how it "is tolerated as the dose is increased, alone or with ritonavir, if there are significant side effects, and how people feel after taking it", say the documents. Phase 2 will do the same but with "multiple doses", while in Phase 3, tablet and liquid forms of the drug will be tested, as will the impact of eating on top of it. Every detail has been specified in advance. In Phase 3, for example, a high-fat breakfast is defined as: "2 eggs fried in butter, 2 strips of pork bacon, 2 slices of toast with butter, 4 oz. of hash brown potatoes, and 8 oz. of whole milk... eaten in 20 minutes". Bringing a new drug to market is a long and difficult process and even if PF-07321332 is found to be well tolerated in humans, formal Phase 3 trials would need to follow to establish whether the drug worked against people exposed to SARS-CoV-2. Prof Ward has also warned of more practical problems. The antiviral Tamiflu that she helped create costs about pounds 25 a course and is still not widely prescribed in the UK against seasonal flu because of its price tag, despite some 20,000 people dying of the disease in Britain each year. For Pfizer and PF-07321332, it is a "race against time", she said. They not only need to produce a drug that works but need to do it while SARS-CoV- 2 still presents a major public health threat. Share this article in your social network * Share via email * Share on Facebook * Share on Twitter * Open more share options Close Share this Story: Pfizer is testing a pill that, if successful, could become first-ever home cure for COVID-19 + Copy Link + Email Email + Facebook Facebook + Twitter Twitter + Reddit Reddit + Pinterest Pinterest + LinkedIn LinkedIn + Tumblr Tumblr Latest National Stories Advertisement Story continues below This advertisement has not loaded yet, but your article continues below. Montreal Gazette Headline News Sign up to receive daily headline news from the Montreal Gazette, a division of Postmedia Network Inc. Email Address [ ] * There was an error, please provide a valid email address. [Sign Up] By clicking on the sign up button you consent to receive the above newsletter from Postmedia Network Inc. You may unsubscribe any time by clicking on the unsubscribe link at the bottom of our emails. Postmedia Network Inc. | 365 Bloor Street East, Toronto, Ontario, M4W 3L4 | 416-383-2300 Thanks for signing up! A welcome email is on its way. If you don't see it please check your junk folder. The next issue of Montreal Gazette Headline News will soon be in your inbox. We encountered an issue signing you up. Please try again Trending This Week in Flyers Comments Postmedia is committed to maintaining a lively but civil forum for discussion and encourage all readers to share their views on our articles. Comments may take up to an hour for moderation before appearing on the site. We ask you to keep your comments relevant and respectful. We have enabled email notifications--you will now receive an email if you receive a reply to your comment, there is an update to a comment thread you follow or if a user you follow comments. Visit our Community Guidelines for more information and details on how to adjust your email settings. Categories * News * Opinion * Sports * Business * Arts * Life * Driving * E-Paper --------------------------------------------------------------------- Follow the Montreal Gazette * Visit our Facebook page in a new tab * Visit our Twitter page in a new tab * Visit our YouTube page in a new tab * Visit our Instagram page in a new tab --------------------------------------------------------------------- Secondary Links * Advertise With Us * Digital Ad Registry * Site Map * Contact * Privacy - Updated * Terms of Use * Copyright Visit the Postmedia Brands page 365 Bloor Street East, Toronto, Ontario, M4W 3L4 (c) 2021 Montreal Gazette, a division of Postmedia Network Inc. All rights reserved. Unauthorized distribution, transmission or republication strictly prohibited. Notice for the Postmedia Network This website uses cookies to personalize your content (including ads), and allows us to analyze our traffic. Read more about cookies here. By continuing to use our site, you agree to our Terms of Service and Privacy Policy. OK